TNFRSF17 and Miyoshi myopathy: In the context of preclinical and clinical activity in the setting of IMiD-refractory MM, mezigdomide has the potential to treat advanced disease with continued immunomodulatory activity, including in poor-prognosis settings such as triple-class-refractory disease, high-risk cytogenetics, the presence of extramedullary disease, and prior exposure to anti-BCMA therapy.